Role of liver biopsy in the evaluation of hepatitis C virus infection in HIV coinfection

Clinical Infectious Diseases

Volumn 40, Issue SUPPL. 5, 2005, Pages

  Sterling, Richard K ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; LIVER ENZYME; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

AUTOPSY; COMORBIDITY; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; ENZYME ANALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LABORATORY TEST; LIFE EXPECTANCY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; MEDICAL ASSESSMENT; MEDICAL INFORMATION; MORBIDITY; MORTALITY; NON INVASIVE MEASUREMENT; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RNA ANALYSIS; SCORING SYSTEM; SUPERINFECTION; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOPSY; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER; RISK ASSESSMENT;

EID: 16844368842     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427439     Document Type: Conference Paper

References (53)

1. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138:197-207.
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-7.
3. Tedaldi EM, Hullsiek KH, Malvestutto CD, et al. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 2003; 36:1313-7.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
5. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.
6. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997; 350:1425-31.
7. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to endstage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-7.
8. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33:240-7.
9. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183:1112-5.
10. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
11. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity - a challenge for the hepatologist? J Hepatol 2002; 36:283-94.
12. Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 36(Suppl 1):S161-72.
13. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45(Suppl 4):IV1-IV11.
14. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36(Suppl 1):S152-60.
15. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23:1334-40.
16. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124:97-104.
17. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32:477-81.
18. Perrault J, McGill DB, Ott BJ, Taylor WF. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 1978; 74:103-6.
19. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995; 15:70-81.
20. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-5.
21. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
22. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-93.
23. Lebovics E, Thung SN, Schaffner F, Radensky PW. The liver in the acquired immunodeficiency syndrome: a clinical and histologic study. Hepatology 1985; 5:293-8.
24. Schneiderman DJ, Arenson DM, Cello JP, Margaretten W, Weber TE. Hepatic disease in patients with the acquired immune deficiency syndrome (AIDS). Hepatology 1987; 7:925-30.
25. Gordon SC, Reddy KR, Gould EE, et al. The spectrum of liver disease in the acquired immunodeficiency syndrome. J Hepatol 1986; 2:475-84.
26. Wilkins MJ, Lindley R, Dourakis SP, Goldin RD. Surgical pathology of the liver in HIV infection. Histopathology 1991; 18:459-64.
27. Cappell MS, Schwartz MS, Biempica L. Clinical utility of liver biopsy in patients with serum antibodies to the human immunodeficiency virus. Am J Med 1990; 88:123-30.
28. Poles MA, Dieterich DT, Schwarz ED, et al. Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:170-7.
29. Bach N, Theise ND, Schaffner F. Hepatic histopathology in the acquired immunodeficiency syndrome. Semin Liver Dis 1992; 12:205-12.
30. Bierhoff E, Fischer HP, Willsch E, et al. Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Arch 1997; 430:271-7.
31. Guido M, Rugge M, Fattovich G, et al. Human immunodeficiency virus infection and hepatitis C pathology. Liver 1994; 14:314-9.
32. Boldorini R, Vigano P, Monga G, et al. Hepatic histology of patients with HIV infection and chronic hepatitis C treated with interferon. J Clin Pathol 1997; 50:735-40.
33. Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. Am J Gastroenterol 1997; 92:1130-4.
34. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The MULTIVIRC Group. Hepatology 1999; 30:1054-8.
35. Allory Y, Charlotte F, Benhamou Y, Opolon P, Le Charpentier Y, Poynard T. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group. Hum Pathol 2000; 31:69-74.
36. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-7.
37. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183:134-7.
38. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257-65.
39. Tural C, Fuster D, Tor J, et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003; 10:118-25.
40. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52:1035-40.
41. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36:491-8.
42. Sterling RK, Contos MJ, Sanyal AJ, et al. The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr 2003; 32:30-7.
43. Sterling RK, Wilson MS, Sanyal AJ, et al. The impact of highly active antiretroviral tehrapy on the spectrum of liver disease in HCV-HIV coinfection. Clin Gastroenterol Hepatol 2004; 2:423-9.
44. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34:1000-5.
45. Shiffman ML, Stewart CA, Hofmann CM, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis 2000; 182:1595-601.
46. Monforte Ade A, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001; 28:114-23.
47. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002; 34:1259-63.
48. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36(Suppl 1):S57-64.
49. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-75.
50. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-26.
51. Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003; 17:721-5.
52. Sterling RK, Fung SK, Marrero JA, et al. A single noninvasive index can predict significant fibrosis in HIV-HCV coinfected patients (abstract 2032). Gastroenterology 2004; 126(4 Suppl 2):A-744.
53. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16:813-28.